Trials / Terminated
TerminatedNCT04684914
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Altimmune, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HepTcell | Intramuscular injection |
| DRUG | Placebo | Intramuscular injection |
Timeline
- Start date
- 2020-12-26
- Primary completion
- 2024-03-27
- Completion
- 2024-04-17
- First posted
- 2020-12-28
- Last updated
- 2025-12-08
- Results posted
- 2025-12-08
Locations
21 sites across 5 countries: United States, Canada, Germany, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04684914. Inclusion in this directory is not an endorsement.